Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals

L Collette; T Burzykowski; KJ Carroll; D Newling; T Morris; Fritz Schröder

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals

L Collette, T Burzykowski, KJ Carroll, D Newling, T Morris, Fritz Schröder

Urology

Research output: Contribution to journal › Article › Academic › peer-review

107 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	6139-6148
Number of pages	10
Journal	Journal of Clinical Oncology
Volume	23
Issue number	25
Publication status	Published - 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Collette, L., Burzykowski, T., Carroll, KJ., Newling, D., Morris, T., & Schröder, F. (2005). Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. Journal of Clinical Oncology, 23(25), 6139-6148.

Collette, L ; Burzykowski, T ; Carroll, KJ et al. / Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 25. pp. 6139-6148.

@article{3001a7a59bb8442ab4f4891959037b67,

title = "Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals",

author = "L Collette and T Burzykowski and KJ Carroll and D Newling and T Morris and Fritz Schr{\"o}der",

year = "2005",

language = "Undefined/Unknown",

volume = "23",

pages = "6139--6148",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "25",

}

Collette, L, Burzykowski, T, Carroll, KJ, Newling, D, Morris, T & Schröder, F 2005, 'Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals', Journal of Clinical Oncology, vol. 23, no. 25, pp. 6139-6148.

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. / Collette, L; Burzykowski, T; Carroll, KJ et al.
In: Journal of Clinical Oncology, Vol. 23, No. 25, 2005, p. 6139-6148.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals

AU - Collette, L

AU - Burzykowski, T

AU - Carroll, KJ

AU - Newling, D

AU - Morris, T

AU - Schröder, Fritz

PY - 2005

Y1 - 2005

M3 - Article

SN - 0732-183X

VL - 23

SP - 6139

EP - 6148

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 25

ER -

Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder F. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. Journal of Clinical Oncology. 2005;23(25):6139-6148.